耳鼻咽喉科・頭頸部外科90巻3号

2018年03月発行

特集 頭頸部癌に対する薬物療法—最新情報

唾液腺癌に対する薬物治療

著者： 多田雄一郎¹

所属機関： ¹国際医療福祉大学三田病院頭頸部腫瘍センター

ページ範囲：P.244 - P.251

文献概要

POINT

●標準的薬物療法はいまだに確立されていない。

●多彩な組織型を有するため，それぞれの臨床的特徴をよく理解し，薬物療法の適応を検討する。

●唾液腺導管癌・腺癌NOS・低分化癌などでは，白金製剤とタキサン系抗癌剤併用療法，アンドロゲン遮断療法，あるいは抗HER2療法の有用性が報告されている。

●腺様囊胞癌での薬物療法の開始は慎重に適応を検討する。

参考文献

1）Tamaki T, et al：The burden of rare cancer in Japan：application of the RARECARE definition. Cancer Epidemiol 38：490-495, 2014

2）El-Naggar AK, et al（eds）：WHO classification of head and neck tumours, 4th edition. IARC, Lyon, 2017, pp159-202

3）Japan Society for Head and Neck Cancer, Cancer Registry Committee：Report of head and neck cancer registry of Japan, clinical statistics of registered patients, 2014, major salivary glands（2014）. Head and Neck Cancer 42（Supplement）：103-115, 2016

4）日本頭頸部癌学会（編）：唾液腺癌（耳下腺癌）．頭頸部癌診療ガイドライン2013年版，金原出版，東京，2013，pp38-41

5）NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers：https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf（accessed 2017/10/30）

6）日本臨床腫瘍学会（編）：頭頸部がん薬物療法ガイダンス．金原出版，東京，2015

7）岡田拓朗・他：再発転移唾液腺癌に対するカルボプラチン・ドセタキセル併用療法の検討．頭頸部癌43：176，2017

8）Nakano K, et al：Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients：differences in responses by different pathological diagnoses. Acta Otolaryngol 136：948-951, 2016

9）藤井博文・他：頭頸部癌に対するtaxotere（TXT），cisplatin（CDDP）併用第Ⅰ-Ⅱ相試験．日癌治療会誌37：516，2002

10）Tahara M, et al：Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. Cancer Chemother Pharmacol 68：769-776, 2011

11）Fushimi C, et al：A prospective phase Ⅱ study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma；Ann Oncol 2017 Dec 1, doi：10.1093/annonc/mdx 771［Epub ahead of print］

12）Takahashi H, et al：Trastuzumab and docetaxel for HER-2 positive unresectable salivary gland carcinoma：updated results of a phase Ⅱ trial. In：Abstract for 9th international conference on head and neck cancer. Seattle, WA：American Head and Neck Society；July 16-20, 2016

13）Licitra L, et al：Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase Ⅱ trial of 22 patients. Ann Oncol 7：640-642, 1996

14）Laurie SA et al：A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer：a trial of the NCIC Clinical Trials Group. Cancer 116：362-368, 2010

15）Airoldi M, et al：Cisplatin＋vinorelbine treatment of recurrent or metastatic salivary gland malignancies（RMSGM）：a final report on 60 cases. Am J Clin Oncol 40：86-90, 2017

16）久保田　彰・他：唾液腺進行癌に対する根治あるいは術後の化学放射線同時併用療法の検討．日耳鼻116：415，2013

17）Nakashima T, et al. Is there a role of adjuvant treatment for salivary duct carcinoma? J Laryngol Otol 129 Suppl 2：S98-S101, 2015

18）Takase S, et al：Biomarker immunoprofile in salivary duct carcinomas：clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8：59023-59035, 2017

19）Gilbert MR, et al：A 20-Year Review of 75 Cases of Salivary Duct Carcinoma. JAMA Otolaryngol Head Neck Surg 142：489-495, 2016

20）Williams MD, et al：Differential expression of hormonal and growth factor receptors in salivary duct carcinomas：biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31：1645-1652, 2007

21）Weigelt B, et al：Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 9：58-64, 2011

22）Alfieri S, et al：Systemic therapy in metastatic salivary gland carcinomas：A pathology-driven paradigm? Oral Oncol 66：58-63, 2017

gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 24：1169-1176, 2011

24）Cohen RB, et al：Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE028 study of pembrolizumab. J Clin Oncol 34（15_suppl）：6017, 2016

V600 mutations. N Engl J Med 373：726-736, 2015

kinase domain duplications across multiple tumor types and response to RAF inhibitor therapy. JAMA Oncol 2：272-274, 2016

identification in a mammary analogue secretory carcinoma（MASC）. Ann Oncol 27：920-926. 2016

28）Wang K, et al：Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22：6061-6068, 2016

29）Piha-Paul SA et al：Salivary duct carcinoma：targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29：727-230, 2011

30）Locati LD et al：Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther 15：678-682, 2014

31）Urban D et al：Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw 13：288-290, 2015

32）Manfredi M et al：223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma. Clin Nucl Med 42：391-393, 2017

33）van Boxtel W, et al：Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. Oral Oncol 72：198-200, 2017

34）Jaspers HC, et al：Androgen receptor-positive salivary duct carcinoma：a disease entity with promising new treatment options. J Clin Oncol 29：e473-476, 2011

35）Yajima Y, et al：Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors：a retrospective study. Ann Oncol 23：Abs 1796, 2012

36）Locati LD, et al：Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38：724-731, 2016

37）Boon E, et al：Salivary duct carcinoma：clinical outcomes and prognostic factors in 157 patients and results of androgen deprivation therapy in recurrent disease（n＝31）-study of the Dutch head and neck society（DHNS）. J Clin Oncol 34［suppl；abstr 6016］, 2016

38）Haddad R, et al：Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase Ⅱ study. Oral Oncol 39：724-727, 2003

39）Perissinotti AJ, et al：The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res 33：2587-2591, 2013

40）Locati LD, et al：Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 41：97-98, 2005

41）Nabili V, et al：Salivary duct carcinoma：a clinical and histologic review with implications for trastuzumab therapy. Head Neck 29：907-912, 2007

42）Limaye SA, et al：Trastuzumab for the treatment of salivary duct carcinoma. Oncologist 18：294-300, 2013

43）Perissinotti AJ, et al：The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res 33：2587-2591, 2013

44）Falchook GS, et al：A phase Ⅰ trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs 33：177-86, 2015

45）De Block K, et al：Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane：a series of six patients. Acta Clin Belg 71：383-388, 2016

46）Thorpe LM, et al：Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. Head Neck 39：E40-E44, 2017

47）Kurzrock R, et al：Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations：Interim data from MyPathway. ASCO meeting 2017, abstract #6086

48）Licitra L, et al：Cisplatin in advanced salivary gland carcinoma. A phase Ⅱ study of 25 patients. Cancer 68：1874-1877, 1991

49）Gilbert J, et al：Phase Ⅱ trial of taxol in salivary gland malignancies（E1394）：a trial of the Eastern Cooperative Oncology Group. Head Neck 28：197-204, 2006

50）Debaere D, et al：Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT 7：1-6, 2011